We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR
Read MoreHide Full Article
Seattle Genetics, Inc. along with Japanese partner Astellas Pharma, Inc announced positive results from the first cohort of the phase II EV-201 study on enfortumab vedotin. The candidate is being evaluated in the pivotal study for the treatment of patients with advanced/metastatic urothelial cancer, who were previously treated with both a checkpoint inhibitor (PD-1/PD-L1) and platinum-based chemotherapy.
Data from the study showed that enfortumab vedotin rapidly shrank tumors, having achieved an objective response rate (ORR) of 44% in majority of the patients while complete responses (CR) were observed in 12% of the given subject population. The median duration of tumor response was 7.6 months.
The company presented this data at the annual meeting of the American Society of Clinical Oncology (ASCO) held in Chicago.
In the study, the responses observed were similar for patients, who had experienced worst prognosis including those whose disease had spread to the liver, having undergone three or more previous lines of therapy and for those, who did not respond to treatment with Merck’s (MRK - Free Report) PD-1/L1 inhibitor, Keytruda.
Shares of Seattle Genetics were up almost 4.3% following the news on Monday. In fact, the stock has rallied 22.1% so far this year against the industry’s dip of 1.9%.
Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) targeting Nectin-4, a cell adhesion molecule, that is expressed in many solid tumors. Both Seattle Genetics and Astellas plan to submit a biologics license application (BLA) for enfortumabvedotin to the FDA later this year.
We would like to remind investors that last July 2018, Seattle Genetics and Astellas initiated the phase III EV-301 study on enfortumab vedotin in patients with advanced urothelial cancer, who previously received both a checkpoint inhibitor (PD-1/PD-L1) and platinum-based chemotherapy. Both companies also completed the cohort enrollment in EV-201 study for the same.
The phase III EV-301 study will support the regulatory filing for a potential approval of the candidate. The companies continue to evaluate enfortumab vedotin combined with Merck’s Keytruda in first-line setting.
Notably, Enfortumab vedotin was granted a Breakthrough Therapy designation by the FDA for the given indication last March.
Meanwhile, Seattle Genetics also presented three-year follow up data from the phase III ECHELON-1 and ECHELON-2 studies at the annual meeting of ASCO. The frontline phase III ECHELON-1 study compared Adcetris plus (Adriamycin, vinblastine and dacarbazine) AVD with ABVD (Adriamycin, bleomycin, vinblastine and dacarbazine) for treating patients with stage III/IV frontline classical Hodgkin lymphoma. The study continues to demonstrate Adcetris’ superior clinical activity in combination with chemotherapy when compared to ABVD for treating frontline Hodgkin lymphoma.
Zacks Rank & Stocks to Consider
Seattle Genetics currently carries a Zacks Rank #4 (Sell).
Acorda’s loss per share estimates have been narrowed 6.5% for 2019 and 6.9% for 2020 over the past 60 days.
Repligen’s earnings estimates have been revised 13.3% upward for 2019 and 12% for 2020 over the past 60 days. The stock has surged 30.6% year to date.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1% and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR
Seattle Genetics, Inc. along with Japanese partner Astellas Pharma, Inc announced positive results from the first cohort of the phase II EV-201 study on enfortumab vedotin. The candidate is being evaluated in the pivotal study for the treatment of patients with advanced/metastatic urothelial cancer, who were previously treated with both a checkpoint inhibitor (PD-1/PD-L1) and platinum-based chemotherapy.
Data from the study showed that enfortumab vedotin rapidly shrank tumors, having achieved an objective response rate (ORR) of 44% in majority of the patients while complete responses (CR) were observed in 12% of the given subject population. The median duration of tumor response was 7.6 months.
The company presented this data at the annual meeting of the American Society of Clinical Oncology (ASCO) held in Chicago.
In the study, the responses observed were similar for patients, who had experienced worst prognosis including those whose disease had spread to the liver, having undergone three or more previous lines of therapy and for those, who did not respond to treatment with Merck’s (MRK - Free Report) PD-1/L1 inhibitor, Keytruda.
Shares of Seattle Genetics were up almost 4.3% following the news on Monday. In fact, the stock has rallied 22.1% so far this year against the industry’s dip of 1.9%.
Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) targeting Nectin-4, a cell adhesion molecule, that is expressed in many solid tumors. Both Seattle Genetics and Astellas plan to submit a biologics license application (BLA) for enfortumabvedotin to the FDA later this year.
We would like to remind investors that last July 2018, Seattle Genetics and Astellas initiated the phase III EV-301 study on enfortumab vedotin in patients with advanced urothelial cancer, who previously received both a checkpoint inhibitor (PD-1/PD-L1) and platinum-based chemotherapy. Both companies also completed the cohort enrollment in EV-201 study for the same.
The phase III EV-301 study will support the regulatory filing for a potential approval of the candidate. The companies continue to evaluate enfortumab vedotin combined with Merck’s Keytruda in first-line setting.
Notably, Enfortumab vedotin was granted a Breakthrough Therapy designation by the FDA for the given indication last March.
Meanwhile, Seattle Genetics also presented three-year follow up data from the phase III ECHELON-1 and ECHELON-2 studies at the annual meeting of ASCO. The frontline phase III ECHELON-1 study compared Adcetris plus (Adriamycin, vinblastine and dacarbazine) AVD with ABVD (Adriamycin, bleomycin, vinblastine and dacarbazine) for treating patients with stage III/IV frontline classical Hodgkin lymphoma. The study continues to demonstrate Adcetris’ superior clinical activity in combination with chemotherapy when compared to ABVD for treating frontline Hodgkin lymphoma.
Zacks Rank & Stocks to Consider
Seattle Genetics currently carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the healthcare sector include Acorda Therapeutics, Inc. and Repligen Corp. (RGEN - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Acorda’s loss per share estimates have been narrowed 6.5% for 2019 and 6.9% for 2020 over the past 60 days.
Repligen’s earnings estimates have been revised 13.3% upward for 2019 and 12% for 2020 over the past 60 days. The stock has surged 30.6% year to date.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1% and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>